BioSpace News Archive

Keros Therapeutics, Inc. announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences.

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

Belite Bio, Inc announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2023, and provide a general business update.

Poseida Therapeutics, Inc. today announced that the Company will participate in the following upcoming investor conferences in November.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences.

ENB Therapeutics, Inc. today announced top-line results from the dual combination arm of the Phase 1b ENBOLDEN-101 study, evaluating ENB-003 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced refractory cancers.

Myrtelle Inc. today announced that Christopher Janson , M.D. will deliver a presentation entitled “Translation of Gene Therapy Brain Biomarkers from Nonclinical Science to Clinical Trials: A Case Study in Canavan Disease” on Tuesday, November 7, 2023, at the 5th Annual Gene Therapy for Neurological Disorders Summit in Boston, Massachusetts.

National Resilience, Inc. today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.

Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2023 and provided business highlights.

PreciseDx® announced that its analytical validation study for its PreciseBreast™ assessment has been published in the November 3, 2023 issue of Clinical Breast Cancer.